Cargando…

Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration

INTRODUCTION: Recombinant human soluble thrombomodulin (rTM) is reportedly excreted by the kidneys; therefore, the recommended dose for patients with renal impairment is one-third of the standard dose. The aim of this study was to evaluate whether this reduced dose of rTM achieves effective drug con...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Eizo, Yamazaki, Shingo, Setoguchi, Daisuke, Sadahiro, Tomohito, Tateishi, Yoshihisa, Suzuki, Tatsuya, Ishii, Itsuko, Oda, Shigeto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318446/
https://www.ncbi.nlm.nih.gov/pubmed/28271063
http://dx.doi.org/10.3389/fmed.2017.00015
_version_ 1782509189779685376
author Watanabe, Eizo
Yamazaki, Shingo
Setoguchi, Daisuke
Sadahiro, Tomohito
Tateishi, Yoshihisa
Suzuki, Tatsuya
Ishii, Itsuko
Oda, Shigeto
author_facet Watanabe, Eizo
Yamazaki, Shingo
Setoguchi, Daisuke
Sadahiro, Tomohito
Tateishi, Yoshihisa
Suzuki, Tatsuya
Ishii, Itsuko
Oda, Shigeto
author_sort Watanabe, Eizo
collection PubMed
description INTRODUCTION: Recombinant human soluble thrombomodulin (rTM) is reportedly excreted by the kidneys; therefore, the recommended dose for patients with renal impairment is one-third of the standard dose. The aim of this study was to evaluate whether this reduced dose of rTM achieves effective drug concentrations that are comparable to those of the standard dose in treating sepsis-induced disseminated intravascular coagulation (DIC) during continuous hemodiafiltration (CHDF). METHODS: Eight patients in an intensive care unit were randomized to receive either reduced-dose (0.02 mg/kg, n = 4) or standard-dose (0.06 mg/kg, n = 4) rTM. We evaluated the effect of standard dose in comparison to that of reduced dose on the pharmacokinetics (PKs) of rTM for the sepsis-induced DIC patients receiving CHDF. Patients received rTM during a 30-min infusion for six consecutive days. PK parameters of rTM were analyzed using the one-compartment model. RESULTS: The elimination half-life, clearance (T1/2), and distribution volume of sTM were similar between the reduced and standard doses. The maximum concentration (Cmax) and area under the concentration–time curve (AUC) of sTM were approximately 2.5 times higher with standard-dose daily infusions than that with reduced-dose drip infusions (p = 0.041 and 0.062, respectively). The time when the blood concentration of sTM was >500 ng/mL, i.e., the holding time, was significantly longer with standard-dose infusions than those with reduced dose (p = 0.039). CONCLUSION: rTM displayed dose-dependent PK behavior at clinically relevant doses. During CHDF, effective blood concentration of rTM was not achieved with the reduced dose, and rTM was found to not bioaccumulate. Therefore, this pilot study suggests that reducing the rTM dose is unnecessary, even in sepsis-induced DIC patients who require CHDF. However, we need to perform a definitive study to determine the dosage of rTM for the case.
format Online
Article
Text
id pubmed-5318446
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-53184462017-03-07 Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration Watanabe, Eizo Yamazaki, Shingo Setoguchi, Daisuke Sadahiro, Tomohito Tateishi, Yoshihisa Suzuki, Tatsuya Ishii, Itsuko Oda, Shigeto Front Med (Lausanne) Medicine INTRODUCTION: Recombinant human soluble thrombomodulin (rTM) is reportedly excreted by the kidneys; therefore, the recommended dose for patients with renal impairment is one-third of the standard dose. The aim of this study was to evaluate whether this reduced dose of rTM achieves effective drug concentrations that are comparable to those of the standard dose in treating sepsis-induced disseminated intravascular coagulation (DIC) during continuous hemodiafiltration (CHDF). METHODS: Eight patients in an intensive care unit were randomized to receive either reduced-dose (0.02 mg/kg, n = 4) or standard-dose (0.06 mg/kg, n = 4) rTM. We evaluated the effect of standard dose in comparison to that of reduced dose on the pharmacokinetics (PKs) of rTM for the sepsis-induced DIC patients receiving CHDF. Patients received rTM during a 30-min infusion for six consecutive days. PK parameters of rTM were analyzed using the one-compartment model. RESULTS: The elimination half-life, clearance (T1/2), and distribution volume of sTM were similar between the reduced and standard doses. The maximum concentration (Cmax) and area under the concentration–time curve (AUC) of sTM were approximately 2.5 times higher with standard-dose daily infusions than that with reduced-dose drip infusions (p = 0.041 and 0.062, respectively). The time when the blood concentration of sTM was >500 ng/mL, i.e., the holding time, was significantly longer with standard-dose infusions than those with reduced dose (p = 0.039). CONCLUSION: rTM displayed dose-dependent PK behavior at clinically relevant doses. During CHDF, effective blood concentration of rTM was not achieved with the reduced dose, and rTM was found to not bioaccumulate. Therefore, this pilot study suggests that reducing the rTM dose is unnecessary, even in sepsis-induced DIC patients who require CHDF. However, we need to perform a definitive study to determine the dosage of rTM for the case. Frontiers Media S.A. 2017-02-21 /pmc/articles/PMC5318446/ /pubmed/28271063 http://dx.doi.org/10.3389/fmed.2017.00015 Text en Copyright © 2017 Watanabe, Yamazaki, Setoguchi, Sadahiro, Tateishi, Suzuki, Ishii and Oda. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Watanabe, Eizo
Yamazaki, Shingo
Setoguchi, Daisuke
Sadahiro, Tomohito
Tateishi, Yoshihisa
Suzuki, Tatsuya
Ishii, Itsuko
Oda, Shigeto
Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
title Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
title_full Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
title_fullStr Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
title_full_unstemmed Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
title_short Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
title_sort pharmacokinetics of standard- and reduced-dose recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation during continuous hemodiafiltration
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318446/
https://www.ncbi.nlm.nih.gov/pubmed/28271063
http://dx.doi.org/10.3389/fmed.2017.00015
work_keys_str_mv AT watanabeeizo pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration
AT yamazakishingo pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration
AT setoguchidaisuke pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration
AT sadahirotomohito pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration
AT tateishiyoshihisa pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration
AT suzukitatsuya pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration
AT ishiiitsuko pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration
AT odashigeto pharmacokineticsofstandardandreduceddoserecombinanthumansolublethrombomodulininpatientswithsepticdisseminatedintravascularcoagulationduringcontinuoushemodiafiltration